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Discussion
Dr J. Conte (Baltimore, Md). The purpose of your study was to
investigate whether aprotinin directly protects against glutamatergic
excitotoxic injury. I think as far as your data are concerned, you’ve
shown that very nicely. I think we can believe that.
I have 3 methodological questions, and I’d be remiss if I didn’t
go for the low-hanging fruit on this one as well.
The first has to do with the use of fetal tissue. Now, is there any-
thing particular about fetal tissue in cell culture studies like this that
would make it particularly amenable to the prevention of that type of
injury and does it accurately reflect the type of glutamatergic-
stimulated injury that we would see in adolescents or adults in the
whole animal?
The second has to do with the use of a mechanism of slowly
stimulated or slowly triggered excitotoxicity as your slide nicely
demonstrated. Does that accurately reflect the type of injury we
would see with a short period of negative stimulation, such as
hypothermic circulatory arrest, or in situations where we have
embolic types of ischemic injury? Does that slowly triggered
type of mechanism reflect what we would see in that type of real-
life situation?
The third question has to do with aprotinin. Aprotinin was left in
culture for 24 hours. Does that really reflect the mechanism of action
of aprotinin that we would see clinically? Can we translate aproti-
nin’s benefit in a situation where we’ve left it in culture for 24 hours
to a situation where we would use it in near juxtaposition to when an
injury would occur, either hypothermic circulatory arrest or an
ischemic event?
The low-hanging fruit is obvious. In the United States, the Food
and Drug Administration has come down on aprotinin, and many
surgeons are looking twice at whether they want to risk using apro-
tinin because of the reported adverse events and the flurry of law-
suits. Many offices, including our own, are inundated with calls
from patients asking whether they received aprotinin, a week ago,
a year ago, 5 years ago. We’ve even been contacted by malpractice
lawyers who asked if we used aprotinin in a certain patient. Is it
worth it to use it and would you recommend that on the basis of these
studies or on your previous work? If the answer is no, are there other
serine protease inhibitors that might be able to confer the same
advantages?
Dr Iwata. We used fetal cells in our study because adult cells
cannot be grown in an incubator. Therefore we had to use cortical
cells from fetal mice, because they still have potential for growth.
Your second question was why we used slowly triggered excito-
toxicity. It’s a very good question. However, there would be a techni-
cal problem if we used a higher concentration with brief exposure to
NMDAor kainate.Wewould then need to removeNMDAor kainate
to parallel the clinical setting. This is technically difficult, because if
we expose the cells to the air, those cells are going to die. Neurons
cannot be exposed to air. Complete replacement or partial replace-
ment of the bathing medium to allow a briefer exposure to aprotinin
is also difficult because neurons in culture are very sensitive.
In regard to the advisability of using aprotinin clinically, we
realize that this is controversial for adults. However, the majority
of pediatric centers continue to use aprotinin either routinely or
frequently without observing adverse effects.
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